Consolidated Statements of Changes in Equity - USD ($) $ in Millions		Total	Adjustment	Series G	Series D	Preferred Stock	Preferred Stock Series D	Common Stock	Common Stock Series G	Capital Surplus	Capital Surplus Series G	Retained Earnings	Retained Earnings Adjustment	Retained Earnings Series D	Total	[1]	Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2021						26,750,000
Beginning balance (in shares) at Dec. 31, 2021								533,577,000
Beginning balance at Dec. 31, 2021		$ 8,494				$ 520		$ 333		$ 4,743		$ 2,891			$ (288)		$ 295
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		912										900					12
Other comprehensive income (loss)		(1,080)													(1,080)
Cash dividends declared:
Preferred stock		32										32
Common stock		(329)										(329)
Preferred stock issuance (in shares)						4,936,000
Preferred stock issuance		494				$ 494
Common stock repurchased (in shares)								(577,000)
Common stock repurchased		(12)								(12)
Common stock issued for:
Stock options exercised and restricted stock awards (in shares)								4,101,000
Stock options exercised and restricted stock awards		37						$ 3		34
Series G preferred stock conversion		0
Stock-based compensation expense		75								75
Dividends declared - noncontrolling interest of subsidiary preferred stock		(12)															(12)
Ending balance (in shares) at Dec. 31, 2022						31,686,000
Ending balance (in shares) at Dec. 31, 2022								537,101,000
Ending balance at Dec. 31, 2022		8,547	$ 4			$ 1,014		$ 336		4,840		3,430	$ 4		(1,368)		295
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		916										897					19
Other comprehensive income (loss)		180													180
Cash dividends declared:
Preferred stock		32										32
Common stock		(335)										(335)
Preferred stock conversion/redemption (in shares)						(4,936,000)
Preferred stock conversion/redemption		(494)				$ (494)
Common stock repurchased (in shares)								(807,000)
Common stock repurchased		(10)						$ (1)		(9)
Common stock issued for:
Stock options exercised and restricted stock awards (in shares)								2,802,000
Stock options exercised and restricted stock awards		5								5
Series G preferred stock conversion (in shares)									19,743,000
Series G preferred stock conversion		493		$ 493					$ 12		$ 481
Stock-based compensation expense		36						$ 2		34
Dividends declared - noncontrolling interest of subsidiary preferred stock		(19)															(19)
Ending balance (in shares) at Dec. 31, 2023						26,750,000
Ending balance (in shares) at Dec. 31, 2023								558,839,000
Ending balance at Dec. 31, 2023		9,291	$ 8			$ 520		$ 349		5,351		3,964	$ 8		(1,188)		295
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		794										775					19
Other comprehensive income (loss)		60													60
Cash dividends declared:
Preferred stock		29										29
Common stock		(329)										(329)
Preferred stock conversion/redemption (in shares)							(10,000,000)
Preferred stock conversion/redemption					$ (100)		$ (94)					(7)		$ (6)
Common stock repurchased (in shares)	[2]							(39,203,000)
Common stock repurchased	[2]	(626)						$ (25)		(601)
Common stock issued for:
Stock options exercised and restricted stock awards (in shares)								4,644,000
Stock options exercised and restricted stock awards		9						$ 1		8
Series G preferred stock conversion		0
Excise tax on preferred stock redemption		(1)										(1)
Excise tax on common stock repurchased		(6)								(6)
Stock-based compensation expense		59						$ 3		56
Dividends declared - noncontrolling interest of subsidiary preferred stock		$ (19)															(19)
Ending balance (in shares) at Dec. 31, 2024		16,750			0	16,750,000
Ending balance (in shares) at Dec. 31, 2024								524,280,000
Ending balance at Dec. 31, 2024		$ 9,111				$ 426		$ 328		$ 4,808		$ 4,382			$ (1,128)		$ 295

[1] Due to the nature of the preferred stock issued by FHN and its subsidiaries, all components of other comprehensive income (loss) have been attributed solely to FHN as the controlling interest holder.

[2] 2024 includes $604 million repurchased under FHN's general purchase programs.